Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: Does it predict prognosis?

Leukemia and Lymphoma

Volumn 52, Issue 2, 2011, Pages 205-213

  Kim, Jung A ^a   Kim, Seok Jin ^b   Do, In Gu ^b   Jin, Juyoun ^b   Nam, Do Hyun ^b   Ko, Young Hyeh ^b   Kim, Kihyun ^b   Seog Kim, Won ^b  

^a Inje University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Central nervous system; Hypoxia; Lymphoma; Prognosis

Indexed keywords

CYTARABINE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHOTREXATE; PROCARBAZINE; VASCULOTROPIN; VINCRISTINE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL DEATH; CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DRUG MEGADOSE; GROWTH; HUMAN; HUMAN CELL; HYPOXIA; LYMPHOMA; LYMPHOMA CELL; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; MICROENVIRONMENT; MOUSE; MULTIPLE CYCLE TREATMENT; NERVOUS SYSTEM; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STAINING; TISSUE; TISSUE NECROSIS; TREATMENT OUTCOME; XENOGRAFT;

ADULT; AGED; ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 79551624684     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.542261     Document Type: Article

References (30)

1. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88: 1474-1480.
2. Semenza GL. Regulation of cancer cellmetabolismby hypoxiainducible factor 1. Semin Cancer Biol 2009;19:12-16.
3. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-276.
4. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
5. Kim SJ, Rabbani ZN, Dewhirst MW, et al. Expression of HIF- 1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005;49:325-335.
6. Kim SJ, Shin HJ, Jung KY, et al. Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn J Clin Oncol 2007;37:812-819.
7. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515.
8. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia- inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192-1202.
9. Stewart M, Talks K, Leek R, et al. Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Histopathology 2002;40:253-260.
10. Passam FH, Alexandrakis MG, Kafousi M, et al. Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract 2009;205:11-20.
11. Giatromanolaki A, Koukourakis MI, Pezzella F, et al. Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol 2008;26:219-224.
12. Evens AM, Sehn LH, Farinha P, et al. Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with RCHOP. J Clin Oncol 2010;28:1017-1024.
13. Silver I, Erecinska M. Oxygen and ion concentrations in normoxic and hypoxic brain cells. Adv Exp Med Biol 1998;454:7-16.
14. Uhm JE, Kim KH, Yi SY, et al. A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma. Leuk Lymphoma 2009;50:1110-1118.
15. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034-5043.
16. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-346.
17. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
18. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 1999;274:6519-6525.
19. Haugland HK, Vukovic V, Pintilie M, et al. Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys 2002;53:854-861.
20. Mineta H, Miura K, Ogino T, et al. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer 2000;83:775-781.
21. Rasheed S, Harris AL, Tekkis PP, et al. Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br J Cancer 2009;100:1666-1673.
22. Sulkowska M, Wincewicz A, Sulkowski S, Koda M, Kanczuga- Koda L. Relations of TGF-beta1 with HIF-1 alpha, GLUT-1 and longer survival of colorectal cancer patients. Pathology 2009;41:254-260.
23. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 2001;92:634-641.
24. Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ, Airley RE. Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. Eur J Cancer 2004;40:503-507.
25. Shim HK, Lee WW, Park SY, Kim H, So Y, Kim SE. Expressions of glucose transporter types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other Bcell non-Hodgkin's lymphomas. Nucl Med Biol 2009;36:191-197.
26. Shim HK, Lee WW, Park SY, Kim H, Kim SE. Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma. Oncol Res 2009;17:331-337.
27. Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009;30:594-601.
28. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-733.
29. Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001;61:5407-514.
30. Gratzinger D, Zhao S, Tibshirani RJ, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2008;88:38-47.